{"entity":{"id":"nct06007729","kind":"trial","name":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","aka":["ARTEMIS-006"],"tldr":"A phase 2 trial of HS-20093 in head and neck squamous cell carcinoma, run by Hansoh BioMedical R&D Company, now recruiting.","summary":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06007729 by Hansoh BioMedical R&D Company, with 170 participants planned, started 2023-12-18 and due to reach its primary completion in 2025-12-12. Interventions recorded: HS-20093. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06007729","url":"https://clinicaltrials.gov/study/NCT06007729"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["hs-20093"],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06007729","phase":"2","setting":"ARTEMIS-006: A Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Administration of HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","started":"2023-12-18","startedType":"actual","enrolled":170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06007729/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}]}}